According to research published in the journal FEBS Open Bio, this drug helps repair DNA damage in brain cells and reduce inflammation. Both of these factors play an important role in the early stages of Alzheimer’s._x000D_
_x000D_
In experiments on mice, researchers saw that KCL-286 showed positive effects in protecting brain cells from damage and reducing inflammation, which has raised hopes that in the future this drug may not only reduce symptoms but also slow down the disease. According to Jonathan Corcoran, co-author of the study and Professor of King’s College London, this drug has successfully completed a phase one human safety trial on healthy volunteers._x000D_
He said that now the biggest obstacle to its testing on Alzheimer’s patients is not scientific but funding because the drug is ready for the next stage of clinical trials._x000D_
_x000D_
However, experts say that further large-scale clinical trials on Alzheimer’s patients are necessary to fully confirm the efficacy and safety of this drug.
